Results 191 to 200 of about 888,335 (393)

Clinical Study to Evaluate Drug Interactions of Cannabidiol with Citalopram and Morphine in Healthy Adults

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Cannabidiol (CBD) is one of the most abundant bioactive cannabinoids. Research has demonstrated CBD’s ability to inhibit metabolic enzymes like cytochrome P450 (CYP) and UDP‐glucuronosyltransferase (UGT), potentially leading to drug interactions. However, clinical knowledge gaps remain, particularly with regard to drugs that are more commonly taken by ...
Pablo Salcedo   +11 more
wiley   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott   +7 more
wiley   +1 more source

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

open access: yesNew England Journal of Medicine, 2016
R. Navari   +9 more
semanticscholar   +1 more source

The Prevalence and Burden of Avoidant/Restrictive Food Intake Disorder (ARFID) Symptoms in the Adult General Population of the UK and USA

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Introduction Avoidant/Restrictive Food Intake Disorder (ARFID) is a feeding and eating disorder characterized by avoidant/restrictive eating behaviors that lead to medical and/or functional impairments. While ARFID is increasingly recognized within pediatric populations and specialist clinics, data on its prevalence and burden within the adult
Grace Brownlow   +4 more
wiley   +1 more source

Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist

open access: yesDiabetes, Metabolic Syndrome and Obesity
Silvia Gentinetta,1,* Francesca Sottotetti,2,* Matteo Manuelli,3 Hellas Cena2,3 1Novo Nordisk Italia SpA, Roma, Italy; 2Laboratory of Dietetics and Clinical Nutrition, Department of Public Health, Experimental and Forensic Medicine, University of
Gentinetta S   +3 more
doaj  

Home - About - Disclaimer - Privacy